Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
|Articles|February 25, 2013
Mini-quiz: Major Depressive Disorder
Major depression is a common chronic illness within the general US population. What is the approximate prevalence for MDD in the US population?
Advertisement
Major depression is a common chronic illness within the general US population. How common? Take the quiz, learn more.
For the answer,
Answer:c
Major depression is a common chronic illness within the general US population, with a prevalence of approximately 5% to 10%.
For more on this topic, please see
Advertisement
Related to this article
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Treating PTSD Among Veterans at Risk for Suicide
2
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
3
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5